Abeona Therapeutics Inc
ABEO
Company Profile
Business description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 0.10 | 0.00% |
| CAC 40 | 8,330.97 | 16.23 | -0.19% |
| DAX 40 | 25,286.24 | 134.42 | -0.53% |
| Dow JONES (US) | 48,991.38 | 200.61 | -0.41% |
| FTSE 100 | 10,184.35 | 47.00 | 0.46% |
| HKSE | 26,999.81 | 151.34 | 0.56% |
| NASDAQ | 23,361.44 | 348.43 | -1.47% |
| Nikkei 225 | 54,341.23 | 792.07 | 1.48% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,898.86 | 64.88 | -0.93% |
| S&P/ASX 200 | 8,820.60 | 1.20 | -0.01% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |